Skye Bioscience Inc.

Skye Bioscience Inc. is a biotechnology company focused on harnessing the therapeutic potential of cannabinoids. The company's primary function is to develop novel pharmaceuticals that integrate cannabinoids for treating various diseases, especially those related to the eye. Skye Bioscience's key product candidates include drugs aimed at managing and treating eye conditions such as glaucoma, a significant concern within ophthalmology. By targeting these unmet medical needs, the company aims to provide solutions that improve patient outcomes and quality of life. Operating within the biotechnology and healthcare sectors, Skye Bioscience is distinguished by its innovative approach to cannabinoid-derived treatments. The role of Skye Bioscience in the financial market reflects the growing interest and investment in alternative pharmaceutical applications, with cannabinoids offering therapeutic possibilities beyond traditional therapies. As regulatory environments evolve, particularly around cannabis-derived compounds, companies like Skye Bioscience are pivotal in advancing medical science and opening new avenues for treatment.